JOHNSON & JOHNSON |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,594 MXN | +3.06% |
|
+3.43% | -1.96% |
| Sales 2024 * | 88.37B 1,482B 7,043B | Sales 2025 * | 90.78B 1,522B 7,235B | Capitalization | 364B 6,104B 29,004B |
|---|---|---|---|---|---|
| Net income 2024 * | 22.04B 370B 1,756B | Net income 2025 * | 23.09B 387B 1,840B | EV / Sales 2024 * | 4.04 x |
| Net cash position 2024 * | 7B 117B 558B | Net cash position 2025 * | 21.07B 353B 1,680B | EV / Sales 2025 * | 3.78 x |
| P/E ratio 2024 * |
16.8
x | P/E ratio 2025 * |
15.9
x | Employees | 131,900 |
| Yield 2024 * |
3.19% | Yield 2025 * |
3.33% | Free-Float | 77.07% |
More Fundamentals
* Assessed data
More news
Latest transcript on Johnson & Johnson
More recommendations
More press releases
| 1 day | +3.06% | ||
| 1 week | +3.43% | ||
| Current month | +4.39% | ||
| 1 month | +5.70% | ||
| 3 months | -3.47% | ||
| 6 months | +0.18% | ||
| Current year | -1.96% |
1 week
2 501.01
2 593.99
1 month
2 443.012 593.99
Current year
2 443.012 794.00
1 year
2 443.013 000.00
3 years
2 443.013 799.98
5 years
2 440.003 891.00
10 years
1 259.803 891.00
| Managers | Title | Age | Since |
|---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 31/12/88 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 31/12/97 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 04/11/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 24/04/19 |
D. Davis
BRD | Director/Board Member | 72 | 18/06/14 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 21/10/09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/05/24 | 2,594 | +3.06% | 6,155 |
| 10/05/24 | 2,517 | -0.00% | 149 |
| 09/05/24 | 2,517 | +0.04% | 75 |
| 07/05/24 | 2,516 | +0.32% | 613 |
End-of-day quote Mexican S.E., May 12, 2024
More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
151.2
USD
Average target price
173.3
USD
Spread / Average Target
+14.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.98% | 682B | |
| +32.27% | 586B | |
| +18.59% | 327B | |
| +4.07% | 285B | |
| +16.51% | 240B | |
| +9.56% | 209B | |
| -9.00% | 203B | |
| +7.09% | 165B | |
| -1.22% | 161B |
- Stock Market
- Equities
- JNJ Stock
- JNJ * Stock
